These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31747403)

  • 1. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research.
    Maeda S; Osaga S; Maeda T; Takeda N; Tamechika SY; Naniwa T; Niimi A
    PLoS One; 2019; 14(11):e0215192. PubMed ID: 31747403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.
    Nakayamada S; Kubo S; Yoshikawa M; Miyazaki Y; Yunoue N; Iwata S; Miyagawa I; Hirata S; Nakano K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2018 Jan; 57(1):164-174. PubMed ID: 28371836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 and CD24
    Salomon S; Guignant C; Morel P; Flahaut G; Brault C; Gourguechon C; Fardellone P; Marolleau JP; Gubler B; Goëb V
    Arthritis Res Ther; 2017 Feb; 19(1):33. PubMed ID: 28183330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Fukuyo S; Nakayamada S; Iwata S; Kubo S; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2017; 35(4):562-570. PubMed ID: 28516880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.
    Picchianti Diamanti A; Rosado MM; Scarsella M; Germano V; Giorda E; Cascioli S; Laganà B; D'Amelio R; Carsetti R
    Clin Exp Immunol; 2014 Sep; 177(3):630-40. PubMed ID: 24773026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of granzyme B decrease in patients with rheumatoid arthritis responding to abatacept.
    Colombo E; Scarsi M; Piantoni S; Tincani A; Airò P
    Clin Exp Rheumatol; 2016; 34(1):37-41. PubMed ID: 26633185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gene module associated with dysregulated TCR signaling pathways in CD4
    Sumitomo S; Nagafuchi Y; Tsuchida Y; Tsuchiya H; Ota M; Ishigaki K; Nakachi S; Kato R; Sakurai K; Hanata N; Tateishi S; Kanda H; Suzuki A; Kochi Y; Fujio K; Yamamoto K
    J Autoimmun; 2018 May; 89():21-29. PubMed ID: 29146547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis.
    Tada Y; Ono N; Suematsu R; Tashiro S; Sadanaga Y; Tokuda Y; Ono Y; Nakao Y; Maruyama A; Ohta A; Koarada S
    BMC Musculoskelet Disord; 2016 Jul; 17():290. PubMed ID: 27421886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response.
    Scarsi M; Ziglioli T; Airò P
    J Rheumatol; 2010 May; 37(5):911-6. PubMed ID: 20231200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan.
    Kawashiri SY; Endo Y; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aramaki T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Nagano S; Tada Y; Kawakami A
    BMC Musculoskelet Disord; 2021 Jun; 22(1):506. PubMed ID: 34074293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.
    Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Scand J Rheumatol; 2021 Jan; 50(1):15-19. PubMed ID: 32880228
    [No Abstract]   [Full Text] [Related]  

  • 14. Body mass index and response to abatacept in rheumatoid arthritis.
    Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
    Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on relationship among apoptosis rates, number of peripheral T cell subtypes and disease activity in rheumatoid arthritis.
    Ji L; Geng Y; Zhou W; Zhang Z
    Int J Rheum Dis; 2016 Feb; 19(2):167-71. PubMed ID: 24618356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.
    Gazeau P; Alegria GC; Devauchelle-Pensec V; Jamin C; Lemerle J; Bendaoud B; Brooks WH; Saraux A; Cornec D; Renaudineau Y
    Clin Rev Allergy Immunol; 2017 Oct; 53(2):166-176. PubMed ID: 28477078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.
    Pieper J; Herrath J; Raghavan S; Muhammad K; Vollenhoven Rv; Malmström V
    BMC Immunol; 2013 Aug; 14():34. PubMed ID: 23915385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion treatment decreases Th17 cells in patients with rheumatoid arthritis.
    Bounia CA; Liossis SC
    Clin Immunol; 2021 Dec; 233():108877. PubMed ID: 34740842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
    Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
    Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis.
    Inamo J; Kaneko Y; Kikuchi J; Takeuchi T
    Clin Rheumatol; 2021 Sep; 40(9):3615-3626. PubMed ID: 33704594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.